Kingmed Diagnostics(SH:603882) Xin Lang Cai Jing·2025-11-14 02:00Core Viewpoint - The stock of Guangzhou Kingmed Diagnostics Group Co., Ltd. has shown a positive trend, with a year-to-date increase of 15.38% and a recent uptick in trading activity, indicating potential investor interest and market confidence [1][2]. Company Overview - Guangzhou Kingmed Diagnostics Group Co., Ltd. was established on May 26, 2006, and went public on September 8, 2017. The company provides a wide range of diagnostic services to over 23,000 medical institutions across China, covering nearly 80 types of testing technologies and approximately 3,200 testing items [2]. - The company's revenue composition includes 91.20% from medical diagnostic services, 6.45% from sales of diagnostics, and smaller contributions from other services [2]. Financial Performance - For the period from January to September 2025, Kingmed Diagnostics reported a revenue of 4.538 billion yuan, reflecting a year-on-year decrease of 19.23%. The net profit attributable to shareholders was -796.095 million yuan, a significant decline of 184.84% compared to the previous year [2]. - The company has distributed a total of 2.545 billion yuan in dividends since its A-share listing, with 1.647 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Kingmed Diagnostics was 41,700, a decrease of 1.60% from the previous period. The average number of circulating shares per shareholder increased by 1.62% to 11,042 shares [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 35.5057 million shares, which is a reduction of 2.8676 million shares from the previous period [3].